

I 10 Rec'd PCT/US 03 OCT 2005

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EV710806550US
DATE OF DEPOSIT October 3, 2005

Attorney Docket No. P51360

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Callahan et al.	October 3, 2005
Serial No.:	10/517,111	Group Art Unit: Not Yet Assigned
Filed:	December 3, 2004	Examiner: Not Yet Assigned
For:	NF-KB INHIBITORS	

Commissioner for Patents
P.O. Box 1450
Alexandria VA, 22313-1450

Filing of a Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(c) and Certification under 37 C.F.R. §1.97(e)(1) or (e)(2)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except for those documents already part of the filewrapper. This statement is being filed with the required Certification and without any fee, in accordance with the provisions of 37 C.F.R. §1.97(c)(1) and (2), i.e., before a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311.

Serial No.: 10/517,111

Group Art Unit No.: Not Yet Assigned

Statement of Certification. The undersigned hereby certifies either:

(a) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or

(b) that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



Laura K. Madden
Agent for Applicants
Registration No. 48,352

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7339
Facsimile (610) 270-5090
N:\lkm\P5000\P51360 (IKK-b)\Natl Stage\IDS Letter.doc

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P51360	SERIAL NO. 10/517,111
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Callahan et al.		
		FILING DATE December 3, 2004	GROUP Not Yet Assigned	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
		0 747 052	12/11/96	EP			
		WO 02/30353	4/18/02	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Modica et al., “[[(Arylpiperazinyl)alkyl]thio]thieno[2,3-d]pyrimidinone Derivatives as High-Affinity, Selective 5-HT1A Receptor Ligands”. <i>J. Med. Chem.</i> , 40: 574-585 (1997).
	Gewald et al., “2-Amino-thionaphthene”. <i>Chemische Berichte</i> , 101: 1933-1939 (1968).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.